This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Smith & Nephew Updates Share Capital and Voting Rights as of 31 May 2026

Tipranks - Tue Jun 2, 11:08AM CDT

Claim 55% Off TipRanks

Smith & Nephew Snats ( (SNN) ) has shared an update.

On 1 June 2026, Smith & Nephew disclosed that as of 31 May 2026 its total issued share capital comprised 877,733,750 ordinary shares of US$0.20 each, including 27,524,042 shares held in treasury. After excluding treasury stock, the company’s share capital consists of 850,209,708 ordinary shares carrying one vote per share, a key reference figure for investors monitoring their holdings under U.K. disclosure and transparency rules.

The update clarifies the denominator shareholders must use when assessing whether they need to report changes in their ownership stakes under Financial Conduct Authority notification requirements. By providing an exact, up-to-date voting share count, Smith & Nephew reinforces transparency in its capital structure, helping institutional and other significant investors manage regulatory thresholds and disclosure obligations accurately.

The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.

To see Spark’s full report on SNN stock,
click here.

More about Smith & Nephew Snats

Smith & Nephew plc is a global medical technology company listed in the U.K., best known for its orthopaedics, sports medicine and advanced wound management products. It serves healthcare providers and patients worldwide, with a focus on improving surgical outcomes and the treatment of musculoskeletal and wound care conditions.

Average Trading Volume: 1,071,325

Technical Sentiment Signal: Hold

Current Market Cap: $12.7B

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.